By Suvarna Bhatt
San Francisco, May 18 (BioSpace) – Regensburg, Germany based biopharmaceutical company, Antisense Pharma announces that the first patients with colorectal carcinoma (CRC) entered a phase I/II study for the treatment of malignant tumors with AP 12009.
The company has opened its phase I/II-study for patients with colorectal carcinoma (CRC), stages III and IV, as well as malignant melanoma patients, stage III.
Contact Suvarna Bhatt at sbhatt@biospace.com.
